Doctors in Barcelona recently reported an unexpected increase in liver cancer recurrence in people who had been or who are being treated for chronic hepatitis C virus (HCV) infection with new potent all-oral medicines called direct acting antivirals (DAAs). All participants had previously been treated for liver cancer. They had been treated successfully with different combinations of DAAs. In their report, the Barcelona doctors focused on patients treated for HCV between October 2014 and December 2015.
We urge our readers to treat this report from Barcelona with caution. The possible association between exposure to DAAs and liver cancer recurrence may be an association that has arisen by chance. Large numbers (tens of thousands) of people in North America and Western Europe have been treated with DAAs and there have not been reports of multiple cases of recurrent liver cancer in such patients by major clinics. The analysis from Barcelona may have been inadvertently biased by its small size and because the researchers included people at very high risk for recurrence of liver cancer.
As all participants had undergone treatment for liver cancer, they subsequently were considered cured and were under routine clinical and laboratory surveillance for the return of liver cancer. For instance, many participants underwent regular CT, MRI (magnetic resonance imaging) and ultrasound scans of their liver every six months.
The Barcelona doctors focused on 58 participants whose average profile was as follows:
The distribution of therapy for the first occurrence of liver cancer was as follows:
At the time the Barcelona doctors submitted their report, they noted that 40 participants have been monitored for 12 consecutive weeks after the cessation of DAA therapy. Of these 40 people, 39 (98%) have been cured from HCV.
Here is the situation among the remaining 18 participants:
Overall, the entire group of 58 participants has been monitored for nearly six months and their current status is as follows:
Among the three participants who died, their deaths occurred 12, 10 and five months after DAAs had been initiated.
A total of 15 cases of liver cancer recurrence have been found through CT or MRI scans.
The Barcelona doctors claim that the recurrence rate for liver cancer in their report is relatively high, approaching 28%. They do not think that these results are due to tumours being detected very early because of "more intense screening [for liver cancer]." Furthermore, these doctors do not think that DAAs directly caused cancer, as they did not find any evidence for this. Rather, they proposed a complex idea whose key elements are as follows:
Readers should note that this idea, though immunologically interesting, has not been proven.
The Barcelona doctors note that reviews of clinical trials of interferon-based therapy for chronic HCV infection have not found any signal of increased risk for liver cancer. That is true, but a meta-analysis of interferon treatment for HCV infection done by researchers at the University of Toronto, reported earlier in this issue of TreatmentUpdate, has found that even among people who were cured there was still a small risk for the subsequent development of liver cancer. Furthermore, a report from Vienna, also in this issue of TreatmentUpdate, notes that cases of liver cancer have occurred among people who were treated with interferon and not DAAs. In that report, about 11% of participants treated with interferon later developed liver cancer.
Some researchers at the University of Palermo in Italy have reviewed the report from Barcelona. They issued this caution: "A definitive estimate of the likelihood of [liver cancer] recurrence is difficult." This difficulty arises because of many factors (that are beyond the scope of our article).
The Barcelona doctors calculated that they found a 28% rate of liver cancer recurrence and they say that this was greater than what they expected. Yet, according to the Italian researchers who reviewed the Barcelona data and then recalculated the estimated risk of liver cancer, the risk of recurrence should have been between 7% and 13%. The Italian researchers therefore see no need for alarm. Note that the numbers of patients upon which both teams used to base their calculations is small and much caution is needed, as these estimates are not robust.
It is possible that the report from Barcelona contains a major flaw: It was inadvertently over-represented with patients who were at very high risk for the recurrence of liver cancer. This could have biased their conclusions.
Whatever the ultimate reason for the apparently increased rate of liver cancer recurrence noted by the Barcelona doctors, their report has ignited disagreement and controversy. To seek clarity on this issue, many people in the liver field will now look to large databases that have data on hundreds, and in some cases thousands, of patients.
|Caution Needed About Claims of Increased Risk of Liver Cancer Recurrence With Use of DAAs|
|Vienna Doctors Urge Caution When Assessing Possible Associations Between Liver Cancer Recurrence and Use of DAAs|
|Large Review From Three French Studies Finds No Link Between Use of DAAs and Recurrence of Liver Cancer|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|